The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar, along with his colleagues from Surgery, Gastroenterology, Radiation Oncology and Radiology have formed multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine and pancreatic cancer. He is helping to develop the use of stromal agents and gene-targeted therapies in the treatment of pancreatic cancer and neuroendocrine tumors. Dr. Hendifar's research involves studying cachexia in his cancer patients. He has developed a treatment protocol in pancreatic cancer cachexia that will increase understanding of this phenomenon. The goal is to develop new therapies for this condition. One treatment, an anti-inflammatory agent, is already being investigated in colon cancer patients. Dr. Hendifar is also the primary investigator for several trials in the treatment of pancreatic cancer, colon cancer, and neuroendocrine tumors.